Key result
Ularitide decreased pulmonary capillary wedge pressure and improved dyspnoea scores at 6 hours in patients with decompensated heart failure.
Why the study?
Does ularitide improve haemodynamics and dyspnoea in patients with decompensated heart failure?
RCT (n=221)
Double-blind
Randomized
Does ularitide improve haemodynamics and dyspnoea in patients with decompensated heart failure?
In patients with decompensated heart failure, a 24-hour continuous infusion of ularitide lowers cardiac filling pressures and improves dyspnoea without early deleterious effects on renal function.
Answers are grounded in this paper and cite their sources.
Supports acute management of decompensated HF; extends natriuretic peptide evidence with RCT confirmation of hemodynamic and symptomatic effects.
AIMS: Ularitide is a synthetic form of urodilatin, a natriuretic peptide produced in the kidney with vasodilating, natriuretic, and diuretic effects, that offers promise for the management of decompensated heart failure (DHF). We assessed the efficacy and safety of ularitide in treating patients with DHF. METHODS AND RESULTS: In this Phase II randomized, double-blind, placebo-controlled trial, 221 DHF patients received either placebo (n=53) or ularitide at 7.5 ng/kg/min (n=60), 15 ng/kg/min (n=53), or 30 ng/kg/min (n=55) as a 24-h continuous infusion. At 6 h, ularitide demonstrated a significant decrease in pulmonary capillary wedge pressure (P=0.052, P=0.000004, P=0.000002, respectively) and improved dyspnoea score in the 7.5, 15, and 30 ng/kg/min ularitide group (P=0.0026, P=0.0026, P=0.0013, respectively). Ularitide reduced systemic vascular resistance and increased cardiac index for the 15 and 30 ng/kg/min groups (P=0.017, P=0.00002, respectively). Systolic blood pressure (BP) decreased dose dependency. Heart rate and serum creatinine were unchanged through day 3. Most frequently reported drug-related adverse events through day 3 in all ularitide groups were dose-dependent BP decrease and hypotension. CONCLUSION: Ularitide lowered cardiac filling pressures and improved dyspnoea without apparent early deleterious effects on renal function in DHF patients. These results suggest that ularitide may play a role in the management of DHF.
No takes yet. Share an insight, caveat, or question.
Mitrovic et al. (2006) conducted an RCT in Decompensated heart failure (n=221). Ularitide vs. Placebo was evaluated on Decrease in pulmonary capillary wedge pressure and improved dyspnoea score at 6 h (p=P=0.052, P=0.000004, P=0.000002 for PCWP; P=0.0026, P=0.0026, P=0.0013 for dyspnoea). Ularitide decreased pulmonary capillary wedge pressure and improved dyspnoea scores at 6 hours in patients with decompensated heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: